IPHA · Innate Pharma S.A.

This 6-K filing delivers Innate Pharma’s Q1 2026 financial results and pipeline update, representing a HIGH materiality event due to the confluence of near-term liquidity pressure, pivotal trial timing dependencies, and mixed clinical progress across its portfolio. Revenue more than doubled year-over-year to €2.6 million, exclusively attributed to partial or full recognition of proceeds from existing collaboration agreements with AstraZeneca and Sanofi — confirming continued monetization of partnered programs but revealing no new commercial or milestone revenue streams. Critically, the Company’s cash position stands at €25.4 million as of March 31, 2026, explicitly stated to support operations only until the end of Q3 2026. This creates a hard financing deadline ahead of two major H2 2026 catalysts: the PACIFIC-9 Phase 3 readout (monalizumab-led, AstraZeneca-run) and the planned initiation of the lacutamab TELLOMAK-3 confirmatory Phase 3 trial — the latter explicitly conditioned on securing non-dilutive financing via pharma partnering or royalty structures. While IPH4502 shows encouraging early activity in post-enfortumab vedotin urothelial cancer and MATISSE Phase 2 delivered a robust 27.5% pCR rate in NSCLC, the deprioritization of SAR’514 by Sanofi removes a potential near-term value driver. Management commentary emphasizes execution against a leaner organizational structure and strategic focus, yet the absence of updated forward guidance, lack of gross margin or expense detail, and reliance on uncertain financing underscore elevated execution and funding risk for investors.